OBJECTIVE: To explore the effects of Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy on treating H.pylori-related gastritis. METHODS: Eighty-two patients with H. pylori-related gastritis treated...OBJECTIVE: To explore the effects of Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy on treating H.pylori-related gastritis. METHODS: Eighty-two patients with H. pylori-related gastritis treated in our hospital from January 2016 to December 2017 were selected according to the random number table method and divided into experimental group and control group, with 41 patients in each group. The control group was treated with standard triple therapy, while the experimental group was additionally treated with modified Chaihu Guizhi Ganjiang Decoction. The venous blood of one elbow was taken before and after treatment. The concentrations of serum CagA and Hp-NAP were detected by enzyme-linked immunosorbent assay(ELISA). The symptoms were evaluated according to the change of symptom scores before and after the intervention. The H.pylori eradication rate was calculated. RESULTS: There was no significant difference in CagA and Hp-NAP concentrations between the 2 groups before intervention(P > 0.05). After intervention, CagA and Hp-NAP concentrations in experimental group were(19.21±6.27) ng/L and(24.37±6.10) ng/L respectively which were lower than(25.81±7.14) ng/L and(32.09±5.73) ng/L of control group. The differences were statistically significant(P < 0.05). The total effective rate of major symptoms in experimental group was 39 cases(95.12%), which was significantly higher than that of the control group(31 cases, 75.61%). There was statistically significant difference between the 2 groups(P < 0.05). The eradication rate of H.pylori was 38 cases(92.68%) in the experimental group, which was significantly higher than 31 cases(75.61%) of the control group. The difference between the 2 groups was statistically significant(P < 0.05). CONCLUSION: Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy can effectively reduce CagA, Hp-NAP of serum level in patients with H.pylori-related gastritis, improve efficacy of symptoms and eradication rate of H.pylori, and is worthy of clinical promotion.展开更多
为检测胃癌组织中幽门螺杆菌(Helicobacter pylori,Hp)感染及细胞转导与转录激活因子3(signal transducer and activator of transcription 3,Stat3)的活化水平,探讨Hp感染和Stat3活化的相关性以及对胃癌的发生、发展及预后的影响。应...为检测胃癌组织中幽门螺杆菌(Helicobacter pylori,Hp)感染及细胞转导与转录激活因子3(signal transducer and activator of transcription 3,Stat3)的活化水平,探讨Hp感染和Stat3活化的相关性以及对胃癌的发生、发展及预后的影响。应用实时荧光定量PCR检测80例胃癌以及其中50例相应癌旁非癌组织中Hp的相对感染量,同时应用免疫组化EnVision法检测上述样本中活化的p-Stat3水平;并结合患者的临床病理及随访资料进行综合分析。结果显示,(1)胃癌组织中Hp相对感染量显著高于癌旁非癌组织;活化的p-Stat3水平也显著高于癌旁非癌组织(P<0.05)。(2)胃癌组织中Hp相对感染量及p-Stat3水平与患者年龄、性别及组织学分型无明显相关性(P>0.05);Hp相对感染量与胃癌的肿瘤浸润深度、淋巴结转移和TNM分期呈显著正相关(P<0.05),但与远处转移无明显相关性(P>0.05);活化的p-Stat3水平与胃癌的肿瘤浸润深度、远处转移和TNM分期存在明显正相关(P<0.05),但与淋巴结转移无明显相关性(P>0.05)。胃癌中Hp相对感染量与活化p-Stat3水平呈显著正相关(r=0.557,P<0.001)。(3)Kaplan-Meier生存分析显示,Hp相对感染量和p-Stat3的水平均与胃癌患者生存率呈显著负相关(P<0.05)。由此可知,胃癌中Hp感染与Stat3的活化有关,Hp感染可能通过触发Stat3的磷酸化,激活Stat3炎性信号通路,进而参与胃癌的发生发展及预后。Hp感染及Stat3的活化水平可能作为临床上评估胃癌进展及预后的潜在标志物。展开更多
文摘OBJECTIVE: To explore the effects of Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy on treating H.pylori-related gastritis. METHODS: Eighty-two patients with H. pylori-related gastritis treated in our hospital from January 2016 to December 2017 were selected according to the random number table method and divided into experimental group and control group, with 41 patients in each group. The control group was treated with standard triple therapy, while the experimental group was additionally treated with modified Chaihu Guizhi Ganjiang Decoction. The venous blood of one elbow was taken before and after treatment. The concentrations of serum CagA and Hp-NAP were detected by enzyme-linked immunosorbent assay(ELISA). The symptoms were evaluated according to the change of symptom scores before and after the intervention. The H.pylori eradication rate was calculated. RESULTS: There was no significant difference in CagA and Hp-NAP concentrations between the 2 groups before intervention(P > 0.05). After intervention, CagA and Hp-NAP concentrations in experimental group were(19.21±6.27) ng/L and(24.37±6.10) ng/L respectively which were lower than(25.81±7.14) ng/L and(32.09±5.73) ng/L of control group. The differences were statistically significant(P < 0.05). The total effective rate of major symptoms in experimental group was 39 cases(95.12%), which was significantly higher than that of the control group(31 cases, 75.61%). There was statistically significant difference between the 2 groups(P < 0.05). The eradication rate of H.pylori was 38 cases(92.68%) in the experimental group, which was significantly higher than 31 cases(75.61%) of the control group. The difference between the 2 groups was statistically significant(P < 0.05). CONCLUSION: Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy can effectively reduce CagA, Hp-NAP of serum level in patients with H.pylori-related gastritis, improve efficacy of symptoms and eradication rate of H.pylori, and is worthy of clinical promotion.
文摘为检测胃癌组织中幽门螺杆菌(Helicobacter pylori,Hp)感染及细胞转导与转录激活因子3(signal transducer and activator of transcription 3,Stat3)的活化水平,探讨Hp感染和Stat3活化的相关性以及对胃癌的发生、发展及预后的影响。应用实时荧光定量PCR检测80例胃癌以及其中50例相应癌旁非癌组织中Hp的相对感染量,同时应用免疫组化EnVision法检测上述样本中活化的p-Stat3水平;并结合患者的临床病理及随访资料进行综合分析。结果显示,(1)胃癌组织中Hp相对感染量显著高于癌旁非癌组织;活化的p-Stat3水平也显著高于癌旁非癌组织(P<0.05)。(2)胃癌组织中Hp相对感染量及p-Stat3水平与患者年龄、性别及组织学分型无明显相关性(P>0.05);Hp相对感染量与胃癌的肿瘤浸润深度、淋巴结转移和TNM分期呈显著正相关(P<0.05),但与远处转移无明显相关性(P>0.05);活化的p-Stat3水平与胃癌的肿瘤浸润深度、远处转移和TNM分期存在明显正相关(P<0.05),但与淋巴结转移无明显相关性(P>0.05)。胃癌中Hp相对感染量与活化p-Stat3水平呈显著正相关(r=0.557,P<0.001)。(3)Kaplan-Meier生存分析显示,Hp相对感染量和p-Stat3的水平均与胃癌患者生存率呈显著负相关(P<0.05)。由此可知,胃癌中Hp感染与Stat3的活化有关,Hp感染可能通过触发Stat3的磷酸化,激活Stat3炎性信号通路,进而参与胃癌的发生发展及预后。Hp感染及Stat3的活化水平可能作为临床上评估胃癌进展及预后的潜在标志物。
